ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient outcomes"

  • Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium

    Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

    Sara Patrizi1, Megha Tandel2, Derek Boothroyd2 and Joyce Hsu1, 1Stanford Medicine, Children's Health, Palo Alto, CA, 2Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
  • Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium

    Kawasaki Disease Shock Syndrome: A Single Center Cohort

    Monica Bray1, Jennifer Rammel 2, Andrea Ramirez 3, Kristen Sexson 4, Fong Lam 5, Eyal Muscal 1 and Marietta De Guzman 3, 1Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, 2Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, 5Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston

    Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
  • Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium

    Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience

    Ugo Awa1, Monica Bray 2 and Marietta De Guzman 3, 1Baylor College of Medicine, Houston, 2Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

    Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
  • Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium

    Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit

    Jennifer Rammel1, Kristen Staggers 2, Satid Thammasitboon 2, Jorge Coss Bu 2, Amanda Brown 3 and Eyal Muscal 4, 1Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, 2Baylor College of Medicine, Houston, Texas, 3Baylor College of Medicine, Houston, 4Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston

    Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…
  • Abstract Number: 421 • 2019 ACR/ARP Annual Meeting

    An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

    Vibeke Strand1, Philip Mease 2, Ervant Maksabedian 3, Bradley Stolshek 3, Lyrica Liu 3, David Collier 3, Gregory Kricorian 3 and Joseph Merola 4, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 3Amgen Inc., Thousand Oaks, CA, 4Harvard Medical School, Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Health-related quality of life is impacted in patients (pts) with psoriatic arthritis (PsA). Patient-reported outcomes (PROs) are an important means of measuring treatment improvements…
  • Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting

    Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)

    Nathalie Carrier 1, Sophie Roux 2, Ariel Masetto 2, Artur deBrum Fernandes 2, Patrick Liang 2, Meryem Maoui 3 and Gilles Boire2, 1CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, 2Université de Sherbrooke, Sherbrooke, QC, Canada, 3Bristol-Myers Squibb Canada, St-Laurent, QC, Canada

    Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
  • Abstract Number: 438 • 2019 ACR/ARP Annual Meeting

    Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?

    Marilyn Wan1, Jessica Walsh 2, M. Elaine Husni 3, Jose Scher 4, Soumya Reddy 5 and Alexis Ogdie 6, 1University of Pennsylvania, Philadelphia, 2Division of Rheumatology, University of Utah, Salt Lake City, UT, 3Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 4Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 5Division of Rheumatology, New York University School of Medicine, New York, NY, 6Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: The multi-dimensional health assessment questionnaire (MDHAQ) is a patient-reported outcome that is commonly used in clinical practice in the US and comprises of 10…
  • Abstract Number: 439 • 2019 ACR/ARP Annual Meeting

    Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection

    Daniel Furst1, George Wan 2, Jingyu Liu 3, Julie Zhu 3, Laura Bartels-Peculis 3, Mary Panaccio 3 and Roy Fleischmann 4, 1University of California, Los Angeles, CA, 2Mallinckrodt Pharmaceuticals, Bedminster, NJ, 3Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, 4Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive inflammation and irreversible joint damage. Treatment of active disease includes disease-modifying anti-rheumatic drugs (DMARDs)…
  • Abstract Number: 662 • 2019 ACR/ARP Annual Meeting

    Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus

    Brooke Williams1, Bridget Muckian 1, Claire Dykas 2, Christine Peschken 3, Richard Furie 4, Elena Massarotti 5, Vanja sikirica 6, Steven Gilbert 7, Martin Hodge 7 and Peter Lipsky 8, 1AMPEL BioSolutions, Charlottesville, VA, 2AmpelBioSolutions, Charlottesville, VA, 3University of Manitoba, Winnepeg, Canada, 4Northwell Health, Great Neck, NY, 5Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 6Pfizer, Boston, MA, 7Pfizer, Boston, 8AMPEL BioSolutions, LLC, Charlottesville, VA

    Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
  • Abstract Number: 834 • 2019 ACR/ARP Annual Meeting

    Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges

    Shanthini Kasturi1, John Wong 1, Lisa Mandl 2, Timothy McAlindon 3 and Amy LeClair 1, 1Tufts Medical Center, Boston, 2Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, 3Tufts Medical Center, Boston, MA

    Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
  • Abstract Number: 876 • 2019 ACR/ARP Annual Meeting

    “When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study

    Erika Mosor1, Paul Studenic 1, Alessia Alunno 2, Ivan Padjen 3, Wendy Olsder 4, Sofia Ramiro 5, Ilaria Bini 6, Nele Caeyers 7, Laure Gossec 8, Marios Kouloumas 9, Elena Nikiphorou 10, Simon Stones 11, Tanita Wilhelmer 12 and Tanja Stamm 1, 1Medical University of Vienna, Vienna, Austria, 2Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, 3UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, 4Patient Research Partner, Amsterdam, Netherlands, 5Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 6ANMAR Young Patient Advocate, Avellino, Italy, 7Patient Research Partner, Brussels, Belgium, 8Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 9Cyprus League Against Rheumatism, Nicosia, Cyprus, 10King's College London, London, United Kingdom, 11University of Leeds, Leeds, United Kingdom, 12Österreichische Rheumaliga, Bregenz, Austria

    Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…
  • Abstract Number: 1153 • 2019 ACR/ARP Annual Meeting

    Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population

    Alice Fike1, Yanira Ruiz-Perdomo 1 and James Katz 1, 1NIAMS, BETHESDA, MD

    Background/Purpose: The potential for reactivation of tuberculosis (TB) in patients treated with anti-TNF or other immunosuppressive agents has been well described.  Interferon-gamma release assays (IGRA)…
  • Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting

    The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

    Yusuf Yazici1, Sarah Kennedy 2, Chris Swearingen 2 and Jeyanesh Tambiah 2, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC, San Diego

    Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
  • Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting

    Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes

    Jatin Mistry 1, Margaret Sibley 2, Catherine Smith 3, Malama Sumbwanyambe 2 and Patrick Kiely2, 1St George's University of London, London, United Kingdom, 2St George's University Hospitals NHS Trust, London, United Kingdom, 3St Georges University Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
  • Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting

    Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis

    Hubert de BOYSSON1, Eric LIOZON 2, Olivier ESPITIA 3, Aurélie DAUMAS 4, Mathieu VAUTIER 5, Marc LAMBERT 6, Jean-Jacques PARIENTI 7, Alain MANRIQUE 7, David Saadoun 8, Kim Heang Ly 2, Christian Agard 9 and Achille Aouba 10, 1University Hospital of Caen, Caen, France, 2Limoges University Hospital, Limoges, France, 3Nantes University Hospital, Nantes, France, 4Marseille AP-HM, Marseille, France, 5Paris - Pitié salpétrière, Paris, France, 6Lille University Hospital, Lille, France, 7Caen University Hospital, Caen, France, 8AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, 9CHU Nantes, Nantes, France, 10CHU Caen, Caen, France

    Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology